Clinical trials: High-risk Medications
Stable Angina, Ischemic Heart Disease Silent
A Randomized Clinical Evaluation of the BioFreedom™ Stent
The purpose of this study is to demonstrate that a BioFreedom™ Drug Coated Stent is non-inferior to a bare metal stent at one year as measured by the composite safety endpoint of cardiovascular death, myocardial infarction and…
- Conditions
- Stable Angina, Ischemic Heart Disease Silent, ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction, In-stent Coronary Artery Restenosis
- Trial name
- Leaders Free (NCT01623180)
- Testing
- Biofreedom™ Drug Coated Stent (DCS), Gazelle™ Bare Metal Coronary Stent (BMS)
- Where
- Switzerland
- Volunteers
- 2,456 people
- Sponsor
- Biosensors Europe SA
Osteosarcoma, Survival
Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
Treatment strategies for high-grade osteosarcoma with multidrug chemotherapy and resection result in 3-year event-free survival of 60-70%.
- Conditions
- Osteosarcoma, Survival, Chemotherapy Effect, Toxicity, Drug
- Trial name
- MAPAC (NCT04351308)
- Testing
- MAPI chemotherapy, Apatinib Mesylate, Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Hypercholesterolemia, HMG COA Reductase Inhibitor Adverse Reaction
Statin Therapy to Improve Medication Adherence
The purpose of this pilot study is to examine if using genetics can improve statin adherence in patients who should be taking statins but are not because of prior side effects with statins.
- Trial name
- NCT01894217
- Testing
- Genetic testing and reporting for SLCO1B1*5 allele
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Duke University
Substance Use, Mental Health Issue
Community Driven Substance Use Recovery for High Opioid Overdose Areas
The main goal of this current study is to develop and optimize methods for increasing access to, uptake of, and engagement in MAT (Medication Assisted Treatment) among communities of color.
- Conditions
- Substance Use, Mental Health Issue, Opioid Use, Medication Assisted Treatment
- Trial name
- IMANI U (NCT05260047)
- Testing
- IMANI, Telehealth MAT, Traditional MAT plus Referral and Linkage
- Where
- 8 sites in United States
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Yale University
Hypertension
A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension
This was a non-interventional, secondary use of data, retrospective, cohort study. The data extracted in this study was used as secondary use of collected patient information in the database, Japan Medical Data Survey (JAMDAS)…
- Trial name
- NCT06683768
- Where
- United States
- Volunteers
- 40,563 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Breast Cancer
Exercise, Cancer and Cognition: The ECCO-Study
The "ECCO"-study evaluates the efficacy of simultaneous controlled exercise during neo/-adjuvant chemotherapy in breast cancer patients and its effects on neurocognition.
- Trial name
- ECCO (NCT04789187)
- Testing
- High-Intensity-Interval-Training, General Physical Activity Recommendations
- Where
- Austria
- Volunteers
- 126 people
- Sponsor
- Johannes Kepler University of Linz
Primary Glioblastoma
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18…
- Trial name
- NCT05736406
- Testing
- 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
- Where
- 2 sites in United States, France
- Volunteers
- 12 people
- Sponsor
- Hemerion Therapeutics
Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00052884
- Testing
- filgrastim, amifostine trihydrate, melphalan
- Where
- 16 sites in United States
- Volunteers
- 8 people
- Sponsor
- Eastern Cooperative Oncology Group
Fall Related Injury Risk
Reducing Injuries From Medication-Related Falls Using Computerized Alerts for High Risk Patients
Drug-related illness accounts for 5% to 23% of hospital admissions, and is now claimed to be the sixth leading cause of mortality.
- Trial name
- NCT00818285
- Testing
- CDS for psychotropic drug management
- Where
- Canada
- Volunteers
- 5,628 people
- Sponsor
- McGill University
Healthy, Growth Hormone
Ghrelin, Growth Hormone and Growth Factors at High Altitude
Regulation of ghrelin, growth hormone and growth factors at high altitude and their change during ascent to high altitude has not been studied in depth yet.
- Trial name
- NCT00966134
- Testing
- exposure to high altitude
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Opioid Overdose
Project OOPEN: Opioid Overdose Prevention, Education and Intervention
This prospective, randomized emergency department trial will study the effectiveness of an intervention that combines opioid overdose prevention, education and intervention that includes take home naloxone with brief behavioral…
- Trial name
- OOPEN (NCT01788306)
- Testing
- OOPEN+BBCC
- Where
- 3 sites in United States
- Volunteers
- 256 people
- Sponsor
- University of Washington
Potentially Inappropriate Medications
An Intuitive, Non-intrusive, Approach to Reduce Patient Harm From Inappropriate Dosing of High-risk Drugs in Older Adult Patients Across an Urban Safety Net Hospital System
This study will assess whether a modification in the default dose and frequency (the first option a provider sees) during electronic prescribing of a high-risk drug can impact prescribing behavior and subsequent changes in…
- Trial name
- NCT05218343
- Testing
- EHR-based "nudge" interventions
- Where
- 2 sites in United States
- Volunteers
- 8,640 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hemodynamic Instability, Cardiac Output, High
Individualized Perioperative Hemodynamic Goal-directed Therapy in Major Abdominal Surgery (iPEGASUS-trial)
To evaluate the impact of perioperative, algorithm driven, hemodynamic therapy based on individualized fluid and cardiac output optimization on postoperative moderate and severe complications in patients undergoing major…
- Conditions
- Hemodynamic Instability, Cardiac Output, High, Peroperative Complication
- Trial name
- iPEGASUS (NCT03021525)
- Testing
- Individualized Goal Directed Therapy, Control Group
- Where
- 7 sites in Germany, Italy and 1 more
- Volunteers
- 380 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and…
- Trial name
- NCT06948084
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib
- Where
- 32 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer
Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor
This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on…
- Trial name
- NCT03299452
- Testing
- Non Chemotherapy, Chemotherapy and target therapy, Chinese herb medicine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Haining Health-Coming Biotech Co., Ltd.
Overweight, Obesity
Meta-analysis of Fructose-Containing Sugar Sweetened Beverages (SSBs) and Weight Change
Since uncontrolled observational studies first linked fructose to the epidemic of obesity almost a decade ago, it has become a focus of intense concern regarding its role in the obesity epidemic.
- Conditions
- Overweight, Obesity, Diabetes, Prediabetes
- Trial name
- NCT01608607
- Testing
- Fructose-containing sugar sweetened beverages
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- John Sievenpiper
Hypercholesterolemia, Atherosclerosis
Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)
The purpose of this study is to obtain data of the coadministration of ezetimibe and rosuvastatin to support the concomitant use of these two drugs in patients requiring additional cholesterol-lowering management.
- Trial name
- NCT00651144
- Testing
- Ezetimibe + Rosuvastatin, Rosuvastatin, Ezetimibe
- Volunteers
- 40 people
- Sponsor
- Organon and Co
Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
This is an open-label, single-arm, single-cohort, prospective clinical study evaluating neoadjuvant antibody-drug conjugate therapy combined with immunotherapy and sequential radiotherapy followed by radical surgery in patients…
- Trial name
- LUXUS0701 (NCT07720921)
- Testing
- Neoadjuvant radiotherapy, ADC + PD1 monoclonal antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University First Hospital
Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
This phase III trial compares whether the addition of pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer coming back (recurrence) in patients with newly diagnosed…
- Conditions
- Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Trial name
- NCT04214067
- Testing
- Biospecimen Collection, Brachytherapy, Computed Tomography
- Where
- 280 sites in United States, Puerto Rico
- Volunteers
- 164 people
- Sponsor
- National Cancer Institute (NCI)